

BSP Antibigram 2025

GRAM NEGATIVE		ANTIBIOTICS														
1/1/2025-12/31/2025	Number tested	Amoxicillin/Clavulanic Acid	Ampicillin	Cefazolin	Cefepime	Ceftriaxone	Ciprofloxacin	Ertapenem	Gentamicin ^(b)	Levofloxacin	Meropenem	Nitrofurantoin ^(c)	Piperacillin/Tazobactam	Tetracycline	Tobramycin	Trimeth/Sulfa
ORGANISM	PERCENT SUSCEPTIBLE															
<i>Enterobacter cloacae</i> complex	40	•		•	85	•	88		100	90	95	33	•			90
<i>Escherichia coli</i>	904	85		82	92	88	70	#	92	73	100	96	97			78
<i>Klebsiella pneumoniae</i>	194	89		83	90	88	85	#	93	86	99	29	91			83
<i>Proteus mirabilis</i>	134	96		90	99	96	71	#	97	70	100	0	99			84
<i>Pseudomonas aeruginosa</i>	199				87		84			82	92		83			

GRAM POSITIVE		ANTIBIOTICS										
1/1/2025-12/31/2025	Number tested	Ampicillin	Clindamycin	Erythromycin	Gentamycin (High-Level)	Linezolid	Nitrofurantoin ^(c)	Oxacillin	Streptomycin (High-Level)	Tetracycline	Trimeth/Sulfa	Vancomycin
Organism	PERCENT SUSCEPTIBLE											
<i>Enterococcus faecalis</i>	139	100		8	78	99	100		92	17		97
<i>Staphylococcus aureus</i> , ALL	224		65	41		100		63		85	88	100
MRSA only	74		68	15		99		0		78	72	100
MSSA only	150		65	56		100		100		89	95	100
<i>Staphylococcus epidermidis</i>	51		63	43		100		45		86	45	100

85-100% Susceptible

60-84% Susceptible

<60% Susceptible

Not routinely tested. Historical data suggests frequent susceptibility; confirm with microbiology when relevant

• Due to the presence of inducible beta-lactamases, this organism should be considered resistant to the antimicrobial indicated

Shaded boxes indicate organism/antimicrobial combinations not tested routinely

(a) Data with fewer than 30 isolates has poor statistical validity.

(b) Aminoglycoside breakpoints were lowered in 2023 for Enterobacterales and *Pseudomonas aeruginosa*. Gentamicin should no longer be